# Duration of IPV Priming and Antibody Decay

> **NCT03202719** · PHASE4 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 1645 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
- **BIOLOGICAL:** Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
- **BIOLOGICAL:** Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
- **BIOLOGICAL:** Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
- **BIOLOGICAL:** Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
- **BIOLOGICAL:** Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age

## Key facts

- **NCT ID:** NCT03202719
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-05
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 1645 (ACTUAL)
- **Last updated:** 2020-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202719, "Duration of IPV Priming and Antibody Decay". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03202719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*